BioLife Solutions (BLFS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions First Quarter twenty twenty five Shareholder and Analyst Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. I will now turn the call over to Troy Wickerman, Chief Financial Officer of BioLife Solutions. Please go ahead. Speake ...

BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally.About BioLife SolutionsBioLife is a leading developer and suppli ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 ____________________________________________________ BioLife Solutions, Inc. (Exact name of registrant as specified in i ...

3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports First Quarter 2025 Financial Results Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (May 8, 2025) – BioLife Solutions, Inc. (Nasdaq: BLFS ...

BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a gene ...

Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technologyMarks the second acquisition from Bioproduction Innovation Accelerator programBOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("Pan ...

Core Insights - The article introduces Colum Manning as a new contributing analyst for Seeking Alpha, highlighting his background in Economics and Biomedical Engineering, and his interest in finance and investment, particularly in the Venture Capital field focused on Biotech and Healthcare sectors [2]. Group 1 - The analyst aims to identify unique investment opportunities within the Biotech, Healthcare, and Life Sciences industries that can yield returns for readers [2]. - Manning emphasizes the importance of continuous learning in investing, mentioning his engagement with financial news sources like the Wall Street Journal and Bloomberg to stay updated on market trends [2]. - The article reflects a commitment to articulate investment views compellingly, indicating a focus on thorough analysis and communication of insights [2].

The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump’s enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being. This might attract investors to invest in the stock market. However, considering the f ...

BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualifi ...

Company Overview - The company operates as a life sciences entity focused on bioproduction products and services for the cell and gene therapy industry[182]. - The current portfolio includes two revenue lines: cell processing and Evo/ThawSTAR devices, with offerings such as biopreservation media and automated thawing systems[183]. - The company divested its Global Cooling, SciSafe, and CBS businesses, which are now classified as discontinued operations[184][185][186]. Financial Performance - Total revenue for the year ended December 31, 2024, was $82.3 million, an increase of $6.4 million, or 8%, compared to 2023[212]. - Product revenue increased to $76.0 million in 2024, up $7.1 million, or 10%, primarily driven by a $7.7 million, or 12%, increase in cell processing products[213]. - Evo and thaw product line experienced a revenue decrease of $0.6 million, or 19%, in 2024 compared to 2023, attributed to lower volumes of consumable products sold[214]. - Rental revenue for 2024 was $6.1 million, a decrease of $0.5 million, or 7%, compared to 2023, due to a reduction in fleet size from the largest customer[217]. - The net loss for 2024 was $20,184,000, compared to a net loss of $68,002,000 in 2023, representing a significant improvement[293]. - Comprehensive loss for 2024 was $20,202 thousand, compared to $67,668 thousand in 2023, reflecting a decrease of about 70%[296]. Expenses and Cost Management - Total operating expenses decreased by $9.9 million, or 10%, in 2024, totaling $89.4 million compared to $99.3 million in 2023[219]. - Cost of product, rental, and service revenue decreased by $1.3 million, or 4%, in 2024, attributed to a decrease in supply expenses and increased operational efficiencies[220]. - General and administrative expenses decreased by $2.7 million, or 6%, in 2024, primarily due to lower severance and consulting expenses[225]. - Research and development expenses decreased by $4.2 million, or 34%, in 2024, mainly due to reductions in personnel and severance costs[231]. Cash Flow and Liquidity - Cash and cash equivalents increased to $95.4 million in 2024, a 242% rise from $27.9 million in 2023[247]. - Total cash, cash equivalents, and available-for-sale securities reached $109.2 million as of December 31, 2024, up 144% from $44.7 million in 2023[246]. - The company generated $58.3 million in cash from investing activities in 2024, significantly higher than $17.8 million in 2023[255]. - Operating activities provided cash of $8.4 million in 2024, a turnaround from cash used of $12.5 million in 2023[251]. Tax and Valuation - As of December 31, 2024, the company recorded U.S. federal net operating loss carryforwards of approximately $165.2 million, with $38.7 million expiring between 2025 and 2037[209]. - A full valuation allowance on deferred tax assets was recorded as of December 31, 2024, due to cumulative losses and forecasted near-term losses[206]. - The company has an unrecognized tax benefit of $1.2 million related to tax attributes being carried forward as of December 31, 2024[208]. Divestitures and Acquisitions - The company recognized $71.3 million in net proceeds from the SciSafe divestiture and $3.4 million from the CBS divestiture in 2024[244][245]. - The company completed the sale of Global Cooling in Q2 2024 and the sales of CBS and SciSafe in Q4 2024, optimizing its product portfolio towards higher margin revenue streams[368]. - The Company incurred a net loss of $8.9 million on the disposal of Global Cooling, which included $6.7 million in cash funded by the Company and $2.6 million in assumed liabilities[371]. Shareholder Equity and Stock - The company’s total shareholders' equity at the end of 2024 was $348,909 thousand, an increase from $337,663 thousand in 2023[299]. - The company issued 1,649,290 shares of common stock in 2024, increasing total common stock shares to 46,906,765[299]. - Basic and diluted loss per share from continuing operations for 2024 was $(0.25), compared to $(0.42) in 2023[324]. Internal Controls and Compliance - The company identified a material weakness in internal control over financial reporting as of December 31, 2024[281]. - The company is currently evaluating the effects of recently issued accounting standards on its consolidated financial statements, including ASU 2024-03 and ASU 2023-09[358][360].